A Randomized, Double-blind, Placebo-Controlled, Escalating-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS-0777,

Administered for 12 Weeks, in Patients with Multiple Sclerosis

This is an early phase study designed to test the safety of a compound. This is one of the steps necessary before conducting a large clinical trial to determine if the agent CS-0777 is effective in MS. Main Eligibility

Requirements:

• Willing to be assigned to one of three different treatment groups

• Willing to have up to 13 study visits with 2 potential overnight stays required at the

Rocky Mountain MS Center at

Anschutz Medical Campus in

Aurora, CO

• 18-65 years old with a diagnosis of clinically isolated syndrome or a relapsing form of MS

• Not currently taking an FDA-approved MS medication or investigational MS medication

If you are interested in this study in particular, please contact:

Carl M. Hale, BS

MS Clinical Trials Lead Coordinator

Office: 303.724.3736